Meduloc develops an FDA-cleared, sterile, single-use flexible nitinol intramedullary implant and delivery system for long-bone fracture applications in adult and pediatric patients. The platform is positioned to provide fracture stability while preserving anatomy and avoiding joint violation in certain applications. Following regulatory clearance, the company is moving into controlled commercialization and plans an alpha launch in early August 2026 with select surgeons and institutions to build clinical experience and collect feedback. Meduloc intends to use recently raised capital to generate additional clinical evidence and to build the commercial infrastructure required for broader adoption. The company is headquartered in West Chester, Pennsylvania, and has attracted regional investor support from Greater Philadelphia and statewide life-sciences funding organizations.

Total raised

$4M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2026